These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


481 related items for PubMed ID: 25545374

  • 1. High suppressor of cytokine signaling-3 expression impairs STAT3-dependent protective effects of interleukin-22 in ulcerative colitis in remission.
    Xu AT, Li Y, Zhao D, Shen J, Xu XT, Qiao YQ, Zhu MM, Wang TR, Cui Y, Ai LY, Ran ZH.
    Inflamm Bowel Dis; 2015 Feb; 21(2):241-50. PubMed ID: 25545374
    [Abstract] [Full Text] [Related]

  • 2. Increased suppressor of cytokine signaling-3 expression predicts mucosal relapse in ulcerative colitis.
    Li Y, Nuij VJ, Baars JE, Biermann K, Kuipers EJ, Peppelenbosch MP, de Haar C, Janneke van der Woude C.
    Inflamm Bowel Dis; 2013 Jan; 19(1):132-40. PubMed ID: 22535619
    [Abstract] [Full Text] [Related]

  • 3. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis.
    Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ, van der Woude CJ.
    Gut; 2010 Feb; 59(2):227-35. PubMed ID: 19926618
    [Abstract] [Full Text] [Related]

  • 4. Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6/IFN-γ-induced vascular smooth muscle cells.
    Xiang S, Dong NG, Liu JP, Wang Y, Shi JW, Wei ZJ, Hu XJ, Gong L.
    J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):615-622. PubMed ID: 24142708
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical significance of mucosal suppressors of cytokine signaling 3 expression in ulcerative colitis.
    Miyanaka Y, Ueno Y, Tanaka S, Yoshioka K, Hatakeyama T, Shimamoto M, Sumii M, Chayama K.
    World J Gastroenterol; 2007 Jun 07; 13(21):2939-44. PubMed ID: 17589943
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
    Oguro T, Ishibashi K, Sugino T, Hashimoto K, Tomita S, Takahashi N, Yanagida T, Haga N, Aikawa K, Suzutani T, Yamaguchi O, Kojima Y.
    Eur J Cancer; 2013 May 07; 49(7):1715-24. PubMed ID: 23274199
    [Abstract] [Full Text] [Related]

  • 10. IL-9 promotes the pathogenesis of ulcerative colitis through STAT3/SOCS3 signaling.
    Tian L, Li Y, Zhang J, Chang R, Li J, Huo L.
    Biosci Rep; 2018 Dec 21; 38(6):. PubMed ID: 30369485
    [Abstract] [Full Text] [Related]

  • 11. DMBT1 is a novel gene induced by IL-22 in ulcerative colitis.
    Fukui H, Sekikawa A, Tanaka H, Fujimori Y, Katake Y, Fujii S, Ichikawa K, Tomita S, Imura J, Chiba T, Fujimori T.
    Inflamm Bowel Dis; 2011 May 21; 17(5):1177-88. PubMed ID: 20824812
    [Abstract] [Full Text] [Related]

  • 12. STAT1, STAT6 and adenosine 3',5'-cyclic monophosphate (cAMP) signaling drive SOCS3 expression in inactive ulcerative colitis.
    Li Y, Deuring J, Peppelenbosch MP, Kuipers EJ, de Haar C, van der Woude CJ.
    Mol Med; 2012 Dec 20; 18(1):1412-9. PubMed ID: 23154639
    [Abstract] [Full Text] [Related]

  • 13. IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer.
    Li Y, Deuring J, Peppelenbosch MP, Kuipers EJ, de Haar C, van der Woude CJ.
    Carcinogenesis; 2012 Oct 20; 33(10):1889-96. PubMed ID: 22739025
    [Abstract] [Full Text] [Related]

  • 14. Hes1 promotes the IL-22-mediated antimicrobial response by enhancing STAT3-dependent transcription in human intestinal epithelial cells.
    Murano T, Okamoto R, Ito G, Nakata T, Hibiya S, Shimizu H, Fujii S, Kano Y, Mizutani T, Yui S, Akiyama-Morio J, Nemoto Y, Tsuchiya K, Nakamura T, Watanabe M.
    Biochem Biophys Res Commun; 2014 Jan 17; 443(3):840-6. PubMed ID: 24342613
    [Abstract] [Full Text] [Related]

  • 15. Signal transducer and activator of transcription 3 (STAT3) and Suppressor of Cytokine Signaling (SOCS3) balance controls cytotoxicity and IL-10 expression in decidual-like natural killer cell line NK-92.
    Braunschweig A, Poehlmann TG, Busch S, Schleussner E, Markert UR.
    Am J Reprod Immunol; 2011 Oct 17; 66(4):329-35. PubMed ID: 21385272
    [Abstract] [Full Text] [Related]

  • 16. Interleukin 11 signaling components signal transducer and activator of transcription 3 (STAT3) and suppressor of cytokine signaling 3 (SOCS3) regulate human endometrial stromal cell differentiation.
    Dimitriadis E, Stoikos C, Tan YL, Salamonsen LA.
    Endocrinology; 2006 Aug 17; 147(8):3809-17. PubMed ID: 16709613
    [Abstract] [Full Text] [Related]

  • 17. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease.
    Andoh A, Shioya M, Nishida A, Bamba S, Tsujikawa T, Kim-Mitsuyama S, Fujiyama Y.
    J Immunol; 2009 Jul 01; 183(1):687-95. PubMed ID: 19535621
    [Abstract] [Full Text] [Related]

  • 18. Human β-defensin-2 enhances IFN-γ and IL-10 production and suppresses IL-17 production in T cells.
    Kanda N, Kamata M, Tada Y, Ishikawa T, Sato S, Watanabe S.
    J Leukoc Biol; 2011 Jun 01; 89(6):935-44. PubMed ID: 21367976
    [Abstract] [Full Text] [Related]

  • 19. Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis.
    Yu LZ, Wang HY, Yang SP, Yuan ZP, Xu FY, Sun C, Shi RH.
    World J Gastroenterol; 2013 May 07; 19(17):2638-49. PubMed ID: 23674871
    [Abstract] [Full Text] [Related]

  • 20. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease.
    Tang R, Yang G, Zhang S, Wu C, Chen M.
    Inflamm Bowel Dis; 2014 Nov 07; 20(11):1950-61. PubMed ID: 25208103
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 25.